Literature DB >> 8875130

Quinupristin-dalfopristin.

H M Bryson1, C M Spencer.   

Abstract

Quinupristin-dalfopristin (RP 59500) is an injectable streptogramin antibiotic. It possesses a wide spectrum of activity against Gram-positive bacteria including methicillin-resistant staphylococci, glycopeptide-resistant. Enterococcus faecium and penicillin-resistant pneumococci. Quinupristin-dalfopristin has activity against some anaerobes and selected Gram-negative pathogens. Quinupristin-dalfopristin, by way synergism of between its 2 components, is unaffected by most forms of bacterial resistance. Rare forms of macrolide-lincosamide-streptogramin group B resistance may affect its activity; however, at present the incidence of strains with this type of resistance remains low. Quinupristin-dalfopristin is bactericidal against streptococci and staphylococci but has weak or no bactericidal activity against enterococci. In a compassionate use programme, 67% of 95 evaluable patients with vancomycin-resistant Gram-positive infections or intolerant of vancomycin showed improvement with eradication of infection.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8875130     DOI: 10.2165/00003495-199652030-00006

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  43 in total

1.  In-vitro activity of RP 59500, a semisynthetic streptogramin, against staphylococci and streptococci.

Authors:  J C Pechère
Journal:  J Antimicrob Chemother       Date:  1992-07       Impact factor: 5.790

2.  In vitro antistaphylococcal activity and testing of RP 59500, a new streptogramin, by two methods.

Authors:  K E Aldridge; D D Schiro; L M Varner
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

3.  Sequence of a staphylococcal plasmid gene, vga, encoding a putative ATP-binding protein involved in resistance to virginiamycin A-like antibiotics.

Authors:  J Allignet; V Loncle; N el Sohl
Journal:  Gene       Date:  1992-08-01       Impact factor: 3.688

4.  RP 59500, a new streptogramin highly active against recent isolates of North American staphylococci.

Authors:  G L Archer; P Auger; G V Doern; M J Ferraro; P C Fuchs; J H Jorgensen; D E Low; P R Murray; L B Reller; C W Stratton
Journal:  Diagn Microbiol Infect Dis       Date:  1993 Mar-Apr       Impact factor: 2.803

5.  Treatment of CAPD-peritonitis due to glycopeptide-resistant Enterococcus faecium with quinupristin/dalfopristin.

Authors:  W A Lynn; E Clutterbuck; S Want; V Markides; S Lacey; T R Rogers; J Cohen
Journal:  Lancet       Date:  1994-10-08       Impact factor: 79.321

6.  In vitro activities of a streptogramin (RP59500), three macrolides, and an azalide against four respiratory tract pathogens.

Authors:  A L Barry; P C Fuchs
Journal:  Antimicrob Agents Chemother       Date:  1995-01       Impact factor: 5.191

7.  In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci, and enterococci.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

8.  Bactericidal activity and kinetics of RP 59500 in a mouse model of Staphylococcus aureus septicaemia.

Authors:  N Berthaud; G Montay; B J Conard; J F Desnottes
Journal:  J Antimicrob Chemother       Date:  1995-08       Impact factor: 5.790

9.  Susceptibilities of penicillin-susceptible and -resistant strains of Streptococcus pneumoniae to RP 59500, vancomycin, erythromycin, PD 131628, sparfloxacin, temafloxacin, win 57273, ofloxacin, and ciprofloxacin.

Authors:  S K Spangler; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

10.  In-vitro activity of RP 59500, a new synergic antibacterial agent, against Legionella spp.

Authors:  J Dubois; J R Joly
Journal:  J Antimicrob Chemother       Date:  1992-07       Impact factor: 5.790

View more
  10 in total

1.  Enterococcal endocarditis: can we win the war?

Authors:  Jose M Munita; Cesar A Arias; Barbara E Murray
Journal:  Curr Infect Dis Rep       Date:  2012-08       Impact factor: 3.725

2.  Pulmonary Infections in Ventilated Patients: Diagnostic and Therapeutic Options.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-06       Impact factor: 3.725

3.  In vitro activity of quinupristin/dalfopristin and newer quinolones combined with gentamicin against resistant isolates of Enterococcus faecalis and Enterococcus faecium.

Authors:  E J Giamarellos-Bourboulis; H Sambatakou; P Grecka; H Giamarellou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1998-09       Impact factor: 3.267

4.  In vitro activities of quinupristin-dalfopristin and the streptogramin RPR 106972 against Mycoplasma pneumoniae.

Authors:  K Izumikawa; Y Hirakata; T Yamaguchi; R Yoshida; H Tanaka; H Takemura; S Maesaki; K Tomono; M Kaku; K I Izumikawa; S Kamihira; S Kohno
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

5.  Antimicrobial activity of quinupristin-dalfopristin.

Authors:  D H Bouanchaud
Journal:  Drugs       Date:  1996-11       Impact factor: 9.546

Review 6.  Management of multidrug-resistant enterococcal infections.

Authors:  C A Arias; G A Contreras; B E Murray
Journal:  Clin Microbiol Infect       Date:  2010-06       Impact factor: 8.067

7.  In vitro and in vivo effects of quinupristin-dalfopristin against Pneumocystis carinii.

Authors:  P D Walzer; A Ashbaugh; M Collins; M T Cushion
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

Review 8.  Streptogramins and their potential role in geriatric medicine.

Authors:  B M Lomaestro; L L Briceland
Journal:  Drugs Aging       Date:  1998-12       Impact factor: 3.923

9.  Site-specific mutations in the 23S rRNA gene of Helicobacter pylori confer two types of resistance to macrolide-lincosamide-streptogramin B antibiotics.

Authors:  G Wang; D E Taylor
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

10.  A Mixture of Atropisomers Enhances Neutral Lipid Degradation in Mammalian Cells with Autophagy Induction.

Authors:  Keisuke Kobayashi; Satoshi Ohte; Taichi Ohshiro; Narihiro Ugaki; Hiroshi Tomoda
Journal:  Sci Rep       Date:  2018-08-14       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.